SynthesisScientific reports2025
Meta-analysis and in-silico functional characterization of the SNCA variant rs356220 in Parkinson's disease.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Roles of mitophagy and immune infiltration in Parkinson's disease: new perspectives from bioinformatics analysis and A53T transgenic mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Investigating the molecular mechanisms of glutamine metabolism and mitochondria-related biomarkers in Alzheimer's disease through transcriptomics and experimental validation.European journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of Parkinson's disease (PD) is influenced by genetic factors, particularly the Synuclein-Alpha (SNCA) gene, which encodes the alpha-synuclein (α-syn) protein involved in dopaminergic neuron degeneration. This study aimed to explore the relationship between rs356220 and PD risk and to understand its functional impact through computational analysis. We thoroughly reviewed nine databases regarding the association between this variant and PD risk. Firstly, a meta-analysis of 9 articles, consisting of 10 studies with 11,638 cases and 37,393 controls was conducted, that identified the C allele of rs356220 as a protective factor against PD (Odds Ratio (OR) 0.91, 95% Confidence Interval (CI): 0.88-0.94, P = 3.82E-08)). Subsequently, we characterized the functional impact of this non-coding variant in the pathophysiology of PD. In-silico process flow included transcription factor binding site (TFBS) analysis, pathway enrichment analysis, and protein interaction analysis. The TFBS analysis suggested that the C allele may influence multiple factors, while subsequent Pathway and Protein Network analyses identified proteins that enhance SNCA expression. Our investigation therefore reveals that rs356220 influences the dynamics of the α-syn protein through interactions with BAD, CANX, SLC18A1, and IRF1, potentially advancing the progression of PD. This research emphasizes the need for holistic study approaches to explore the intricacies of complex disorders like PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.